Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythaemia: challenges and evidence-based management.

Claire N Harrison1

  • 1Department of Haematology, St Thomas Hospital, Lambeth Palace Road, London, UK. claire.harrison@gstt.nhs.uk

British Journal of Haematology
|July 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.

British journal of haematology·2026
Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026
Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026
Same author

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

Therapeutic advances in hematology·2026

Essential thrombocythaemia, a blood disorder, presents risks of clots, bleeding, and transformation into other conditions. This review covers its causes, management, and specific aspects like JAK2 mutations and hydroxyurea.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Essential thrombocythaemia (ET) is a chronic myeloproliferative neoplasm.
  • ET is characterized by thrombotic and hemorrhagic complications.
  • Long-term risks include transformation to myelofibrosis or acute leukemia.

Purpose of the Study:

  • To review current concepts in the etiology and management of Essential Thrombocythaemia.
  • To discuss specific areas including JAK2 mutations and hydroxyurea's leukaemogenicity.
  • To explore the implications of the MRC PT1 study.

Main Methods:

  • Literature review of current concepts in ET.
  • Focused discussion on specific aspects of ET.
  • Reference to recent focused reviews and clinical studies.

Related Experiment Videos

Main Results:

  • Essential thrombocythaemia is clinically and biologically heterogeneous.
  • Janus kinase 2 (JAK2) mutations are recently described.
  • Hydroxyurea (hydroxycarbamide) has leukaemogenic potential.

Conclusions:

  • Understanding ET heterogeneity is crucial for management.
  • JAK2 mutations are significant in ET pathogenesis.
  • Careful monitoring of hydroxyurea therapy is warranted due to leukaemogenicity.